Startup profile · funding coverage
Astromech funding, valuation and investors
Colossal spinout building predictive models of biology using evolutionary and genomic data.
Keep track of Astromech
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Venture
$20M · August 2026
Latest known valuation
$3.8B
Venture · August 2026
Total disclosed equity funding
$20M
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
Stage not recorded · United States
Investors in latest funding
Lead: Bob Nelsen
Other: Builders VC
Overview
Astromech is a computational biology startup spun out of Colossal Biosciences and co-founded by Ben Lamm and George Church. SiliconANGLE reported a $20 million financing led by Bob Nelsen on August 20, 2026, bringing total raised to about $60 million at a $3.8 billion valuation.
Why Astromech is interesting
August 2026 $20M led by Bob Nelsen at a reported $3.8B valuation on ~$60M total raised — the mark is the anomaly; commercial pilots are the next proof.
Product & use cases
Predictive biology models that forecast evolutionary and disease trajectories.
- Longevity research hypothesis generation
- Biosecurity vulnerability forecasting
Key facts
- $20M led by Bob Nelsen; ~$60M total raised (reported)
- Reported valuation: $3.8B
- Colossal Biosciences spinout; longevity as proving ground
Funding history (newest first)
Venture
2026-08 $20M Valuation: $3.8B- Bob Nelsen (lead)
- Builders VC (participant)
Industries
Related funding articles
Venture Capital Tracker pieces that cover Astromech's financing or category context.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.